Givastomig
Based on 1 Customer Validation
Givastomig (ABL111, TJ033721) is a bispecific antibody (BsAb) inhibitor. Givastomig can specifically binds to Claudin18.2 (CLDN 18.2) on the surface of cancer cells and 4-1BB (CD137, TNFRSF9) on the surface of activated T cells and natural killer (NK) cells. Givastomig is engineered to contain a single Fc-domain mutation (asparagine to alanine) to eliminate Fc-effector function. Givastomig-bound cell lines expressing a range of CLDN18.2 levels with high affinity and induced 4-1BB activation only in the context of CLDN18.2 binding. Givastomig can be used for the study of colon carcinoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.556%
- CAS 番号: 2762499-30-7
- 分子量:201.929 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
IgG1-kappa-[scFv-lambda-heavy]2
Human
TNFRSF9 & CLDN18
Givastomig binds to human CLDN18.2 VLP and human 4-1BB protein with high affinity, achieving an equilibrium dissociation constant (KD = 1.698 × 10-10/9.88 × 10-9 M)[1].
Givastomig (0.001-1000 nM, 1 h) specifically binds to CLDN18.2 (EC50 = 0.13 nM) and does not cross-react with its isoform CLDN18.1 expressed in normal lung tissue[1].
Givastomig (0.001-1000 nM, 30 min) shows a stronger binding affinity to all the tested CHO-K1-hCLDN18.2 expressing high, medium and even low level of CLDN18.2 than the control monoclonal antibody[1].
Givastomig (6 h) is co-cultured with NF-κB/4-1BB reporter Jurkat cell lines, which induces strong NF-κB signaling activation, while when co-cultured with CLDN18.2+ cells, it does not activate NF-κB signaling[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Givastomig (0.4-10 mg/kg, i.v., once a week, for a total of three cycles) shows that the anti-tumor activity in colon carcinoma mouse models is dose-dependent[1].
Givastomig (10-100 mg/kg, i.v., once a week, for 5 times) demonstrates excellent safety in cynomolgus monkeys[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C57BL/6-Tnfrsf9tm1 (TNFRSF9) (humanized h4-1BB) mice at the age of 6-8 weeks were subcutaneously inoculated with human CLDN18.2 expressing MC38 (MC38hCLDN18.2) colon carcinoma tumor cells (5×105 cells)[1].
-
Dosage:4 mg/kg
-
Administration:I.v., Biweekly
-
Result:The tumor almost completely disappeared.
Fifty-four days after the initial tumor inoculation, cured mice were challenged again with MC38hCLDN18.2 tumor cells. All cured mice developed resistance to the new tumor challenge, while untreated juvenile mice developed tumors.
The tumor infiltration of CD45+ leukocytes and CD8+ T cells was significantly increased, and the CD8+/Treg (regulatory T cell) ratio was improved.
-
Animal Model:Female C57BL/6-Tnfrsf9tm1 (TNFRSF9) (humanized h4-1BB) mice at the age of 6-8 weeks were subcutaneously inoculated with human CLDN18.2 expressing MC38 (MC38hCLDN18.2) colon carcinoma tumor cells (5×105 cells)[1].
-
Dosage:0.4 mg/kg, 1 mg/kg, 2 mg/kg, 5 mg/kg, 10 mg/kg
-
Administration:I.v., once a week, for a total of three cycles
-
Result:The antitumor activity is dose-dependent. Low doses (0.4, 1 mg/kg) produce partial efficacy, while high doses (5, 10 mg/kg) achieve complete tumor regression.
The increase in intratumoral CD45+ leukocytes and CD8+ T cells is positively correlated with the administered dose.
-
Animal Model:Cynomolgus monkeys (Macaca fascicularis)[1].
-
Dosage:10 mg/kg, 30 mg/kg, 100 mg/kg
-
Administration:I.v., once a week, for 5 times
-
Result:The drug was well tolerated at doses up to 100 mg/kg, with no observed adverse event level (NOAEL).
No drug-related hepatotoxicity was observed.
Peripheral blood immune cell typing and cytokine testing showed no signs of systemic immune activation.
Monitoring of body weight, food consumption, clinical symptoms, electrocardiogram, hematology, and coagulation function revealed no drug-induced abnormalities.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa-[scFv]2-lambda-heavy
ELISA, FACS, Functional assay
-
Immobilized 4-1BB/TNFRSF9 Protein, Human (HY-P7125) can bind Givastomig. The EC50 for this effect is 1.795 ng/mL. -
Immobilized Claudin-18/CLDN18.2 Protein-VLP, Human (HEK293, HY-P78368) can bind Givastomig. The EC50 for this effect is 1.744 ng/mL.
化学情報
-
CAS 番号 2762499-30-7
-
性状 Liquid
-
分子量 201.929 kDa
-
Color Colorless to light yellow
-
別名
TJ-CD4B; ABL111; TJ033721
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (263 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Gao J, et al. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation. J Immunother Cancer. 2023 Jun;11(6):e006704. [Content Brief]
[2]. Ku G, et al. A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2025 Jun 30:10.1158/1078-0432.CCR-24-4280. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Givastomig 関連分類
HY-P990742 関連分類
Powered by Bioz